

"CLEAN SET" OF PENDING CLAIMS

7. (amended) A method of treating a subject having viral hepatitis comprising administering, to the subject, by the peroral route, an oral liquid formulation of natural human  $\alpha$ -interferon at a daily dosage of between 100 and 500 IU.

9. The method of claim 7 wherein the human  $\alpha$ -interferon is obtained from a lymphoblastoid cell culture.

11. (amended) The method of claim 7 wherein the human  $\alpha$ -interferon is obtained from lymphocyte cells.

13. The method of claim 7 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

15. The method of claim 9 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

17. The method of claim 11 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

19. A liquid pharmaceutical composition for oral administration comprising natural human  $\alpha$ -interferon at a concentration between 100 IU/ml and 500 IU/ml, wherein the  $\alpha$ -interferon is obtained from cells of the group consisting of lymphoblastoid cultured cells and lymphocyte cells.

20. (new) An article of manufacture comprising packaging material and a pharmaceutical agent in liquid formulation within said packaging material, wherein the pharmaceutical agent is therapeutically effective for treating viral hepatitis, and wherein the packaging material comprises a label which indicates that the pharmaceutical agent can be used for treating viral hepatitis and has to be administered through the peroral route at a daily dosage

between 100IU and 500 IU, and wherein said pharmaceutical agent is natural human  $\alpha$ -interferon.